Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Yakult Gains Option Rights to Anticancer Drug from Proacta
August 15, 2011
- EC Approves Acquisition of Nycomed by Takeda
August 15, 2011
- First Aid for Choking
August 15, 2011
- Bayer Obtains Exclusive License for Novel Antibiotic
August 15, 2011
- Korosho Taking Public Comments on Proposed GL for Development of Prototype Pandemic Flu Vaccines
August 15, 2011
- RaQualia of Japan Aims to Become Global Drug Discovery Innovator
August 15, 2011
- Santen Creates Subsidiary in India
August 15, 2011
- Korosho Announces Revised Precautions for Diabetes Treatment Metgluco
August 15, 2011
- TOPICS 2 articles
August 15, 2011
- System to Ensure Early Price Settlement Necessary: Non-Partisan Council of Diet Members
August 15, 2011
- Dissolution Test Methods Annexed to ICH Q4B GLs Go into Effect
August 15, 2011
- Taisho Completes Acquisition of Malaysian Company
August 15, 2011
- EPS: Sales Up, Profits Down due to Slump of CRO Business
August 15, 2011
- JPO's WG to Resume Discussions to Revise Patent Term Extension Rule for DDS Preparations
August 15, 2011
- Asahi Kasei to Make Asahi Kasei Kuraray Medical a Wholly-owned Subsidiary
August 15, 2011
- Qol Opens Dispensing Pharmacy at Major Electronics Retail Store
August 15, 2011
- Nichi-Iko to Strengthen Relationships with Wholesalers
August 15, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…